Anyone who suffers from eczema understands how unbearable constant oozing rash and all-around itch can negatively affect their lives and will appreciate Dupilumab. This week, 2 clinical trials (SOLO1, SOLO2) for phase 3, monoclonal antibody dupilumab showed promising evidence of reducing rash in moderate-severe eczema patients by nearly 40%. So what to know about dupilumab? Dupilumab works by binding alpha subunits of IL-4 (interleukin-4) and IL-13 receptors, interfering the signaling of interleukin 4 and 13 pathways (which are inflammatory cytokines pathophysiologically responsible for allergies, asthma, eczema, and atopic dermatitis). Dupilumab is being developed by Regeneron Pharmaceuticals and received priority review status from the FDA, slated for approval as soon as Spring of 2017. If you are suffering from eczema, make sure you talk to your doctor and keep on eye on dupilumab when it hit the market.
For further reading on SOLO1 & SOLO2, see Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis in the New England Journal of Medicine
Featured photo credit: Emma Guttman-Yassky